ArticleCancer biology & therapy2012
Selenium-containing histone deacetylase inhibitors for melanoma management.
Article in Cancer biology & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Critical assessment of selenourea as an efficient small molecule fluorescence quenching probe to monitor protein dynamics.Chemical science · 2023Article
- Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.Pharmaceutics · 2022Review
- The role of SELENBP1 and its epigenetic regulation in carcinogenic progression.Frontiers in genetics · 2022Review
- The Effect of Organoselenium Compounds on Histone Deacetylase Inhibition and Their Potential for Cancer Therapy.International journal of molecular sciences · 2021Review
- Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases.Neurobiology of disease · 2021Review
- Therapeutic Potential of Selenium in Glioblastoma.Frontiers in neuroscience · 2021Review
- Masked Phenolic-Selenium Conjugates: Potent and Selective Antiproliferative Agents Overcoming P-gp Resistance.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Selenium at the redox interface of the genome, metabolome and exposome.Free radical biology & medicine · 2018Review
- Article
- Hydroxamic acid derivatives as histone deacetylase inhibitors: a DFT study of their tautomerism and metal affinities/selectivities.Journal of molecular modeling · 2018Article
- Nanoliposomal delivery of cytosolic phospholipase ANanomedicine : nanotechnology, biology, and medicine · 2018Article
- Selenides and Diselenides: A Review of Their Anticancer and Chemopreventive Activity.Molecules (Basel, Switzerland) · 2018Review
- Tricaproin Isolated FromFrontiers in pharmacology · 2018Article
- A Summary of New Findings on the Biological Effects of Selenium in Selected Animal Species-A Critical Review.International journal of molecular sciences · 2017Review
- Improving pharmacological targeting of AKT in melanoma.Cancer letters · 2017Article
- Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport.Oncotarget · 2017Article
- Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.Molecular cancer therapeutics · 2017Article
- Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.BMC cancer · 2016Article
- Histone deacetylase enzymes as drug targets for the control of the sheep blowfly, Lucilia cuprina.International journal for parasitology. Drugs and drug resistance · 2015Article
- Epigenetic effects of selenium and their implications for health.Epigenetics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Melanoma incidence and mortality rates continue to increase each year. Lack of clinically viable agents, drug combinations, effective targeted delivery approaches and success inhibiting targets in tumor tissue have made this disease one of the most difficult to treat, which makes prevention an important option for decreasing disease incidence and mortality rates. Inhibiting histone deacetylases (HDAC) is an approach currently being explored to more effectively treat melanoma but use for prevention has not been explored. In this study, novel selenium containing derivatives of the FDA approved HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) called 5-phenylcarbamoylpentyl selenocyanide (PCP-SeCN) and Bis{5-phenylcarbamoylpentyl} diselenide (B(PCP)-2Se) were created and efficacy tested for preventing early melanocytic lesion development in skin. Topical application of PCP-SeCN and B(PCP)-2Se inhibited melanocytic lesion development in laboratory-generated skin by up to 87% with negligible toxicological effect. Mechanistically, PCP-SeCN and B(PCP)-2Se inhibited HDAC activity and had new inhibitory properties by moderating Akt activity to induce cellular apoptosis as demonstrated by an increase in the sub-G₀-G₁ cell population, and cleaved caspase-3 as well as PARP levels. Furthermore, PCP-SeCN and B(PCP)-2Se inhibited cell proliferation by inhibiting cyclin D1 expression and increasing p21 levels. Thus, PCP-SeCN and B(PCP)-2Se are potential melanoma chemopreventive agents with enhanced efficacy compared with SAHA due to new PI3 kinase pathway inhibitory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.